Stone Pharmaceutical: Enters into Exclusive Licensing Agreement with Madrigal for SYH2086, Reserving Right to Receive Up to $207.5 Million Total Payment

　　Global Times July 30th ｜ Stone Pharmaceutical (01093.HK) announced that the company has entered into an exclusive licensing agreement with Madrigal Pharmaceuticals, Inc. for the global development, production, and commercialization of its oral small molecule glucagon-like peptide-1 receptor agonist SYH2086. The agreement grants Madrigal exclusive rights to develop, produce, and commercialize SYH2086 globally, while reserving Stone Pharmaceutical's right to develop and sell other oral small molecule GLP-1 receptor agonists in China. The company has the right to receive a total payment of up to $207.5 million, including a prepaid payment of $120 million, potential payments of up to $195.5 million for development, regulatory, and commercial milestones, as well as a high percentage sales commission based on SYH2086's annual net sales.